Dementia Drugs Market 2022-2028

Description

List of Tables

Global Dementia Drugs Market Size, Share & Trends Analysis Report By Type of Dementia (Lewy Body Dementia, Parkinson's Disease, Alzheimer's Disease, and Others), By Type of Drug (Cholinesterase Inhibitors, MAO Inhibitors, Glutamate Inhibitors, and Others), and Forecast 2022-2028

The global dementia drugs market is anticipated to grow at a significant CAGR of around 8.1% during the forecast period. The global dementia drugs market is largely driven due to the increasing prevalence of target diseases, the introduction of new and innovative technologies and drugs, and increased government funding and awareness programs for dementia. The growing senior population suffering from various disorders is also the major factor that is playing a substantial role in the market. However, the low awareness regarding the dementia condition in developing regions turns out to be a restraint for the growth of the dementia drugs market. Additionally, the low diagnosis rate will also hamper the growth of the dementia drug market during the forecast period. Moreover, the side effects of dementia drugs such as nausea, vomiting, loss of appetite, sleep problems, feeling of tiredness will lower the popularity of these drugs in the dementia drug market. For instance, in Aug 2021, the National Institutes of Health (NIH) awarded Tabula Rasa HealthCare (TRHC) a healthcare technology company advancing the safe use of medications.

The global dementia drugs market is segmented based on the type of dementia and type of drugs. Based on the type of dementia, the market is sub-segmented into Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease dementia, and others such as vascular dementia. Further based on the type of drugs, the market is sub-segmented into cholinesterase inhibitors, MAO inhibitors, Glutamate inhibitors, and others. The above-mentioned segments can be customized as per the requirements. For instance, in Feb 2019, Johnson & Johnson Services Inc., Takeda Pharmaceutical Co. Ltd and Evotec together joined The Dementia Consortium.

Geographically, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold the largest market share in dementia drugs during the forecast period. The growth of the region is owing to the well-developed healthcare structure in the region. Additionally, the increasing number of patients diagnosed with dementia as well as its associated condition such as Parkinson's disease will also fuel the dementia drugs market growth across the region.

Some of the key players operating in the global dementia drugs market include Teva Pharmaceuticals Industries Ltd., Merck & Co. Inc., Pfizer Inc., GlaxoSmithKline Plc, Aurobindo Pharma Ltd., Biogen Inc., and others. The market players are considerably contributing to the market growth by adopting various strategies including new product launches, mergers, and acquisitions, collaborations with the government, and new drug commercialization to stay competitive in the market. For instance, in June 2021, Aducanumab (Aduhelm) was licensed by the U.S. Food and Drug Administration for the treatment of Alzheimer's disease.

Research Methodology

The market study of the Global dementia drugs market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.
Whitepapers, research papers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Dementia Drugs Market by Dementia Type

2. Global Dementia Drugs Market by Drug Type

The Report Covers:

Comprehensive Research Methodology of the Global Dementia Drugs Market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the market Global Dementia Drugs Market.
Insights about market determinants that are stimulating the Global Dementia Drugs Market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026337

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Dementia Drugs Market
1.1. Recovery Scenario of Global Dementia Drugs Market
1.2. Research Methods and Tools
1.3. Market Breakdown
- 1.3.1. By Segments
- 1.3.2. BY Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Pfizer Inc
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. Teva Pharmaceuticals Industries Ltd
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Merck & Co Inc
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. GlaxoSmithKline Plc
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Cadila Healthcare Ltd
- 3.5.1. Overview
- 3.5.2. Financial Analysis
- 3.5.3. SWOT Analysis
- 3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

Global Dementia Drugs Market by Dementia Type

4.1.1. Lewy Body Dementia
4.1.2. Parkison's Disease Dementia
4.1.3. Alzheimer's Disease Dementia
4.1.4. Others

Global Dementia Drugs Market by Drugs Type

4.1.5. Cholinesterase Inhibitors
4.1.6. MAO Inhibitors
4.1.7. GlutamateInhibitors
4.1.8. Others

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

5.4.1 Latin America

5.4.2 Middle East and Africa

6. Company Profiles

6.1. Abbvie Inc
6.2. ACADIA Pharmaceutical Inc
6.3. Apotex Corp
6.4. Aurobindo Pharma Ltd
6.5. Biogen Inc
6.6. GlaxoSmithKline Plc
6.7. Johnson & Johnson Services, Inc
6.8. Merck & Co Inc
6.9. Mylan Nv
6.10. Novartis International AG
6.11. Pfizer Inc
6.12. Teva Pharmaceutical Industries Ltd